Objective To evaluate the efficacy of combined therapy, sildenafil and inhaled nitric oxide versus monotherapy with inhaled nitric oxide in Pulmonary Hypertension of the Newborn.
Study Design A retrospective study.
Patients and Methods Newborn infants (gestational age greater than 34 weeks) who were presented with pulmonary hypertension from December 2008 to December 2010 were evaluated. Group I (n=14) received monotherapy with iNO and Group II (n=9) received combination therapy with iNO and oral sildenafil. Main outcome was to compare the duration of iNO therapy between groups.
Results Demographic characteristics were similar between the groups. As compared with the groups, combined therapy group had higher mean (SD) age of NICU admission (5.1±8.2 h vs. 21.3±36, h, p=0.01). Combination therapy was associated with early weaning of iNO (4.8±1.5 vs. 13.5±7.6 hours). The result showed that there is a reduced need for iNO therapy compared to monotherapy (75±44.6 vs. 112±95.2), however, the difference was insignificant (p=0.36). The incidence of mortality and outcomes were statistically insignificant between the groups (p>0.05).
Conclusions Combination therapy is significantly more effective in weaning of iNO and reduces the need for iNO therapy that is relatively expensive.